Gilead to present HIV and antiviral research at IDWeek 2026

BofA Securities raised Gilead Sciences' (GILD) price target to $172 from $168, citing positive phase 2 trial data for emvistegrast. The stock trades at $153.07, up 27% year-over-year. Gilead also reported better-than-expected Q2 2026 results, with revenue of $7.8B. BofA maintains a Buy rating. Gilead is involved in collaborations with Assembly Biosciences and MacroGenics.

Gilead Sciences (GILD) reported that its experimental ulcerative colitis pill, emvistegrast, met the main goal in a mid-stage trial, with 66% of patients achieving clinical response. Shares fell 1.42% to $153.555 on 19 October 2026. The company posted a net loss of $10,496m in Q2 2026, reversing from a profit in Q1. The trial data was presented at a European gastroenterology meeting.

Gilead Sciences will present data on its HIV treatments, including Bixlenvo and Biktarvy, at IDWeek 2026. The company will share findings from Phase 3 studies on Bixlenvo's safety and efficacy in patients with comorbidities and renal impairment. Additionally, Gilead will present real-world evidence on the adoption of lenacapavir for HIV prevention and Phase 1b data on GS-1179 for recurrent genital herpes.

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

The FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.